Award
National Institutes of Health 3U01NS136020-03S1
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
Recipient
Massachusetts General Hospital
Award Amount
$3,990,000.00
Ceiling
$3,990,000.00
Awarded
August 22, 2025
Identifier
3U01NS136020-03S1
Award for a clinical trial investigating autologous T cell therapy for ALS, led by Mass General Hospital with NIH funding of approximately $3.99 million for FY 2025.
Description
Clinical research project led by Massachusetts General Hospital to evaluate safety, mechanisms, and efficacy signals of autologous T cell therapy for ALS in high-risk patients, sponsored by RAPA Therapeutics and funded by NIH.